Cantex Pharmaceuticals Receives FDA Orphan Drug Designation for Azeliragon for the Treatment of Pancreatic Cancer

Cantex Pharmaceuticals, Inc. announced that the US FDA has granted Orphan Drug Designation to Cantex’ azeliragon, a once-a-day pill, for the treatment of pancreatic cancer.